The programme had its premiere in 2019 with 14 healthcare startups from all over Europe that tackled five different challenges set up by EIT Health Partners Amgen, Bayer, Ferrer, Janssen and UCB. Read more about the 2019 edition.
The programme targets start-ups with already functioning product/prototype that already entered the market/are about to enter the market. Selection of companies is based on the quality of the business idea, their fit for the selected challenge and the team’s motivation and level of commitment. Please note that only incorporated companies may apply to the programme.
The selected startups will receive a grant to cover travel and accommodation costs and mentoring services through the Mentoring and Coaching Network Platform.
Challenges for 2020
In 2020, five challenges have been released in collaboration with four EIT Health Partners: Amgen, Bayer, Beiersdorf and Boehringer Ingelheim.
Title: Encourage continuity in treatment strategy and treatment optimisation for post-myocardial infarction patients
Looking for: A solution which will create a standardised procedure for post MI patients after discharge
Title: Choosing the right treatment for Multiple Myeloma patients
Looking for: Creation of an algorithm, that would help physicians choosing the right treatment for Multiple Myeloma patients
Title: Disruptive Gene therapies, cell therapies and delivery technologies for different therapeutic areas
Looking for: Disruptive technologies useful in the therapeutic areas of Cardiology, Oncology, Gynecology, Ophthalmology, Hematology and Women’s Health – or ideally for all of those as a platform technology. Breakthrough innovations for other or multiple indications might be of interest as well.
Title: Improving the condition of diabetic skin
Looking for: BioTech, MedTech or Digital Health solutions to improve the condition of diabetic skin
Title: Portable Interstitial Lung Disease (ILD) Diagnostic Tool
Looking for: A solution which could potentially help a wider range of Healthcare Professionals to early diagnose ILDs.
The detailed description of the five challenges can be found here .
The program consists of four different modules with the objective to train and prepare startups to discuss collaboration opportunities with pharma companies.
Application period: 10 February – 30 March 2020, through the EIT Health Optimy platform
If you have any questions regarding the programme, EIT Health Germany is organising two webinars in March 2020.
Barbara Costa ( firstname.lastname@example.org )
Matteo Consonni ( email@example.com )
Gold sponsors Silver sponsor